Combination of liquiritin, isoliquiritin and isoliquirigenin induce apoptotic cell death through upregulating p53 and p21 in the A549 non-small cell lung cancer cells
- Authors:
- Yanling Zhou
- Wing Shing Ho
View Affiliations
Affiliations: School of Life Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, P.R. China
- Published online on: November 14, 2013 https://doi.org/10.3892/or.2013.2849
-
Pages:
298-304
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Liquiritin, isoliquiritin and isoliquirigenin are the active polyphenols present in Glycyrrhiza uralensis which has been used for the treatment of cancer and its complications. The present study was conducted to evaluate the cytotoxicity and antitumor activity of liquiritin, isoliquiritin and isoliquirigenin on human non-small lung cancer cells including apoptosis-induction, inhibition of apoptotic pathways and to explore the underlying mechanism. Lactate dehydrogenase assays, FITC Annexin V staining assay were performed to evaluate cellular cytotoxicity and apoptosis activity. The results showed that pretreatment with these polyphenols induced apoptosis in A549 cells. Liquiritin, isoliquiritin and isoliquirigenin significantly increased cytotoxicity of, and upregulated p53 and p21 and downregulated the apoptotic pathways. Furthermore, it inhibited cell cycle at the G2/M phase. Western blot analysis showed it significantly decreased the protein expression of PCNA, MDM2, p-GSK-3β, p-Akt, p-c-Raf, p-PTEN, caspase-3, pro-caspase-8, pro-caspase-9 and PARP, Bcl-2 in a concentration-dependent manner while the protein expression of p53, p21 and Bax was increased. In addition, Akt pathway was downregulated. These findings suggest that liquiritin, isoliquiritin and isoliquirigenin inhibited the p53-dependent pathway and showed crosstalk between Akt activities. These active polyphenols can be an alternative agent for the treatment of lung cancer.
View Figures |
Figure 1
|
 |
Figure 2
|
 |
Figure 3
|
 |
Figure 4
|
 |
Figure 5
|
 |
Figure 6
|
 |
Figure 7
|
 |
Figure 8
|
 |
Figure 9
|
 |
Figure 10
|
 |
Figure 11
|
View References
|
1
|
Broker LE and Giaccone G: The role of new
agents in the treatment of non-small cell lung cancer. Eur J
Cancer. 38:2347–2361. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jeong SJ, Koh W, Kim B and Kim SH: Are
there new therapeutic options for treating lung cancer based on
herbal medicines and their metabolites? J Ethnopharmacol.
138:652–661. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang QY and Ye M: Chemical analysis of
the Chinese Herbal medicine Gan-Cao (licorice). J Chromatogr A.
1216:1954–1969. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yo YT, Shieh GS, Hsu KF, Wu CL and Shiau
AL: Licorice and Licochalcone-A induce autophagy in LNCaP prostate
cancer cells by suppression of Bcl-2 expression and the mTOR
pathway. J Agric Food Chem. 57:8266–8273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong SJ, Inoue A, Zhu Y, Tanji M and
Kiyama R: Activation of rapid signally pathways and the subsequent
transcriptional regulation for the proliferation of breast cancer
MCF-7 cells by the treatment with an extract of Glycyrrhiza
glabra root. Food Chem Toxicol. 45:2470–2478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fu Y, Hsieh ZC, Guo JQ, Kunicki J, Lee
YWT, Darzynkiewicz Z and Wu JM: Licochalcone-A, a novel flavonoid
isolated from licorice root (Glycyrrhiza glabra), causes G2
and late-G1 arrests in androgen-independent PC-3 prostat cancer
cells. Biochem Biophys Res Commun. 322:263–270. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hsiang CY, Lai IL, Chao DC and Ho TY:
Differential regulation of activator protein 1 activity by
glycyrrhizin. Life Sci. 70:1643–1656. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Satomi Y, Nishino H and Shibata S:
Glycyrrhetinic acid and related compounds induce G1 arrest and
apoptosis in human hepatocellular carcinoma HepG2. Anticancer Res.
25:4043–4047. 2005.PubMed/NCBI
|
|
9
|
Yoon G, Bok YK and Seung HC: Topoisomerase
I inhibition and cytotoxicity of licochalcones A and E from
Glycyrrhiza inflate. Arch Pharm Res. 30:313–316. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang HY and Yang X: Proteases for cell
suicide: functions and regulation of caspases. Microbiol Mol Biol
Rev. 64:821–846. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsarkar F and Li YW: Targeting multiple
signal pathways by chemopreventive agents for cancer prevention and
therapy. Acta Pharmacol Sin. 28:1305–1315. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Beurel E and Jope RS: The paradoxical pro-
and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic
apoptosis signaling pathways. Prog Neurobiol. 79:173–189. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rommel C, Clarke BA, Zimmermann S, Nuñez
L, Rossman R, Reid K, Moelling K, Yancopoulos GD and Glass DJ:
Differentiation stage-specific inhibition of the Raf-MEK-ERK
pathway by Akt. Science. 286:1738–1741. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gottlieb TM, Martinez-Leal JF, Seger R,
Taya Y and Oren M: Cross-talk between Akt, p53 and MDM2: possible
implications for the regulation of apoptosis. Oncogene.
21:1299–1303. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mayo LD and Donner DB: The PTEN, MDM2, p53
tumor suppressor-oncoprotein network. Trends Biochem Sci.
27:462–467. 2002. View Article : Google Scholar : PubMed/NCBI
|
